Patient Assistance Programs and the Anti-Kickback Statute: Charting a Pathway Forward

Pharmaceutical manufacturer-funded patient assistance programs can circumvent the anti-kickback statute by subsidizing patients’ out-of-pocket costs for expensive drugs through ostensibly independent charities, effectively incentivizing use of high-cost medications at federal program expense.